Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
复制标题
DOI：
--
复制
发表时间：
1995-08
期刊：
影响因子：
--
通讯作者：
O. Nielsen;T. Ciardelli;Z. Wu;E. Langholz;I. Kirman
中科院分区：
文献类型：
--
作者：
O. Nielsen;T. Ciardelli;Z. Wu;E. Langholz;I. Kirman
目的炎症性肠道疾病的特征是T细胞活化。活化的T细胞以可溶形式释放白细胞介素-2受体（IL-2 R）。以前已经显示了sIL-2 R α（CD 25）和炎症性肠病的疾病活动性之间的正相关性，而IL-2 R β（CD 122）以前从未在这方面进行过研究。从27例溃疡性结肠炎（UC），31例克罗恩病（CD），和29名健康志愿者的血清。方法根据UC的半定量评分和CD的克罗恩病活动指数对疾病活动进行评分。通过夹心ELISA技术，使用分别对CD 25和CD 122特异的单克隆抗体，评估sIL-2 R α和β链。结果正常对照组sIL-2 R α的中位浓度为4424 pg/ml，UC组为6460 pg/ml（p0.05）。在CD中，非活动期的水平为839 pg/ml，活动期的水平为920 pg/ml（与对照组相比，p > 0.05）。CD患者sIL-2 R α、β链水平与正常对照组（r = 0.16; p > 0.05）呈正相关（r = 0.64; p <0.05）。结论：未来的纵向研究将是必要的，以了解这种新评估的sIL-2 R β（CD 122），这可能会干扰IL-15 R，可用于预测疾病恶化和监测抗炎治疗UC。
OBJECTIVES Inflammatory bowel disease is characterized by T cell activation. Activated T cells shed interleukin-2 receptors (IL-2R) in a soluble form. A positive correlation between sIL-2R alpha (CD25) and disease activity in inflammatory bowel disease has been shown previously, whereas IL-2R beta (CD122) has never before been investigated in this respect. Serum from 27 patients with ulcerative colitis (UC), 31 with Crohn's disease (CD), and 29 healthy volunteers was obtained. METHODS Disease activity was scored according to a semiquantitative score for UC and by Crohn's disease activity index for CD. sIL-2R alpha and -beta chains were assessed by a sandwich ELISA technique using monoclonal antibodies specific for CD25 and CD122, respectively. RESULTS The median concentration of sIL-2R alpha was 4424 pg/ml in healthy controls, 6460 in UC (p 0.05). In CD, the levels were 839 pg/ml in inactive and 920 pg/ml in active disease stages (p > 0.05 vs controls). A positive and significant correlation existed between sIL-2R levels of alpha and beta chains in CD (r = 0.64; p 0.05) or in healthy volunteers (r = 0.16; p > 0.05). CONCLUSION Future longitudinal studies will be necessary to learn whether this newly assessed sIL-2R beta (CD122), which may interfere with IL-15R, could be used to predict disease exacerbation and to monitor anti-inflammatory therapy in UC.